U.S. markets closed
  • S&P Futures

    3,832.25
    -6.75 (-0.18%)
     
  • Dow Futures

    31,496.00
    +31.00 (+0.10%)
     
  • Nasdaq Futures

    12,562.50
    -101.25 (-0.80%)
     
  • Russell 2000 Futures

    2,193.40
    +3.70 (+0.17%)
     
  • Crude Oil

    67.54
    +1.45 (+2.19%)
     
  • Gold

    1,702.70
    +4.20 (+0.25%)
     
  • Silver

    25.67
    +0.38 (+1.51%)
     
  • EUR/USD

    1.1909
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3813
    -0.0015 (-0.11%)
     
  • USD/JPY

    108.3800
    -0.0020 (-0.00%)
     
  • BTC-USD

    50,434.21
    +769.31 (+1.55%)
     
  • CMC Crypto 200

    1,019.96
    +76.79 (+8.14%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,806.89
    -57.43 (-0.20%)
     

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor conferences:

  • Cowen 41st Annual Health Care Conference
    Date: Monday, March 1st at 2:40 p.m. Eastern Time

  • H.C. Wainwright Global Life Sciences Conference
    Date: Tuesday, March 9th at 7:00 a.m. Eastern Time

  • Barclays Global Healthcare Conference
    Date: Wednesday, March 10th at 10:55 a.m. Eastern Time

For presentations that are webcast live, an access link will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentations will also be available on the Sangamo Therapeutics website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, cell therapy, and genome engineering. For more information about Sangamo, visit www.sangamo.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005058/en/

Contacts

Investor Relations & Media Inquiries
Aron Feingold
628.252.7494
afeingold@sangamo.com